These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 17359901)

  • 1. RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery).
    Parker C; Clarke N; Logue J; Payne H; Catton C; Kynaston H; Murphy C; Morgan R; Morash C; Parulekar W; Parmar M; Savage C; Stansfeld J; Sydes M;
    Clin Oncol (R Coll Radiol); 2007 Apr; 19(3):167-71. PubMed ID: 17359901
    [No Abstract]   [Full Text] [Related]  

  • 2. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.
    Lodde M; Lacombe L; Fradet Y
    Urology; 2010 Nov; 76(5):1189-93. PubMed ID: 20303155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
    Parker CC; Clarke NW; Cook AD; Kynaston H; Catton CN; Cross WR; Petersen PM; Persad RA; Saad F; Bower LC; Logue J; Payne H; Forcat S; Goldstein C; Murphy C; Anderson J; Barkati M; Bottomley DM; Branagan J; Choudhury A; Chung PWM; Cogley L; Goh CL; Hoskin P; Khoo V; Malone SC; Masters L; Morris SL; Nabid A; Ong AD; Raman R; Tarver KL; Tree AC; Worlding J; Wylie JP; Zarkar AM; Parulekar WR; Parmar MKB; Sydes MR;
    Lancet; 2024 Jun; 403(10442):2405-2415. PubMed ID: 38763154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.
    Parker CC; Kynaston H; Cook AD; Clarke NW; Catton CN; Cross WR; Petersen PM; Persad RA; Pugh CA; Saad F; Logue J; Payne H; Bower LC; Brawley C; Rauchenberger M; Barkati M; Bottomley DM; Brasso K; Chung HT; Chung PWM; Conroy R; Falconer A; Ford V; Goh CL; Heath CM; James ND; Kim-Sing C; Kodavatiganti R; Malone SC; Morris SL; Nabid A; Ong AD; Raman R; Rodda S; Wells P; Worlding J; Parulekar WR; Parmar MKB; Sydes MR;
    Lancet; 2024 Jun; 403(10442):2416-2425. PubMed ID: 38763153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of androgen deprivation therapy in early salvage radiation among patients with prostate-specific antigen level of 0.5 or less.
    Parekh A; Chen MH; Graham P; Mahal BA; Hirsch AE; Nakabayashi M; Evan C; Kantoff PW; Martin NE; Nguyen PL
    Clin Genitourin Cancer; 2015 Feb; 13(1):e1-6. PubMed ID: 25103271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial comment to Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation.
    Yoshida T
    Int J Urol; 2013 Jul; 20(7):714-5. PubMed ID: 23216631
    [No Abstract]   [Full Text] [Related]  

  • 7. Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621.
    Hurwitz MD; Harris J; Sartor O; Xiao Y; Shayegan B; Sperduto PW; Badiozamani KR; Lawton CAF; Horwitz EM; Michalski JM; Roof K; Beyer DC; Zhang Q; Sandler HM
    Cancer; 2017 Jul; 123(13):2489-2496. PubMed ID: 28323339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage Radiotherapy Versus Hormone Therapy for Prostate-specific Antigen Failure After Radical Prostatectomy: A Randomised, Multicentre, Open-label, Phase 3 Trial (JCOG0401)
    Yokomizo A; Wakabayashi M; Satoh T; Hashine K; Inoue T; Fujimoto K; Egawa S; Habuchi T; Kawashima K; Ishizuka O; Shinohara N; Sugimoto M; Yoshino Y; Nihei K; Fukuda H; Tobisu KI; Kakehi Y; Naito S;
    Eur Urol; 2020 Jun; 77(6):689-698. PubMed ID: 31866092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Reevaluation of MAB therapy and progress of endocrine therapy].
    Klotz L; Payne H; Gillatt D; Keane T; Morris C; Akaza H; Hirao ; Akakura K; Fukagai T
    Gan To Kagaku Ryoho; 2005 May; 32(5):705-28. PubMed ID: 15934164
    [No Abstract]   [Full Text] [Related]  

  • 10. Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.
    Jang JW; Hwang WT; Guzzo TJ; Wein AJ; Haas NB; Both S; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1493-9. PubMed ID: 22401922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer.
    Hellerstedt B
    Urology; 2003 Dec; 62 Suppl 1():79-86. PubMed ID: 14747045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Editorial comment. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Garnick MB
    BJU Int; 2012 Oct; 110(8):1155. PubMed ID: 22369480
    [No Abstract]   [Full Text] [Related]  

  • 13. [Adjuvant hormone therapy in prostatic cancer: after treatment with curative intent. The viewpoint of the urologist].
    Martorana G
    Recenti Prog Med; 2002 Mar; 93(3):179-82. PubMed ID: 11942170
    [No Abstract]   [Full Text] [Related]  

  • 14. [Efficacy of bicalutamide in adjuvant treatment of prostatic carcinoma after primary therapy with curative aim. The viewpoint of the surgeon].
    Rigatti P; Scattoni V
    Recenti Prog Med; 2002 Mar; 93(3):183-5. PubMed ID: 11942171
    [No Abstract]   [Full Text] [Related]  

  • 15. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
    Shipley WU; Seiferheld W; Lukka HR; Major PP; Heney NM; Grignon DJ; Sartor O; Patel MP; Bahary JP; Zietman AL; Pisansky TM; Zeitzer KL; Lawton CA; Feng FY; Lovett RD; Balogh AG; Souhami L; Rosenthal SA; Kerlin KJ; Dignam JJ; Pugh SL; Sandler HM;
    N Engl J Med; 2017 Feb; 376(5):417-428. PubMed ID: 28146658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial comment.
    Shepard DR
    Urology; 2010 May; 75(5):1137. PubMed ID: 20451735
    [No Abstract]   [Full Text] [Related]  

  • 17. Hormone therapy for radiorecurrent prostate cancer.
    Payne H; Khan A; Chowdhury S; Davda R
    World J Urol; 2013 Dec; 31(6):1333-8. PubMed ID: 22996761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comment on "secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot study".
    de la Taille A
    World J Urol; 2014 Dec; 32(6):1625-6. PubMed ID: 24413818
    [No Abstract]   [Full Text] [Related]  

  • 19. Androgen deprivation in prostate cancer and the long-term risk of fracture.
    Ojeda S; Lloret M; Naranjo A; Déniz F; Chesa N; Domínguez C; Lara PC
    Actas Urol Esp; 2017 Oct; 41(8):491-496. PubMed ID: 28259363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.
    Lau YK; Chadha MK; Litwin A; Trump DL
    J Hematol Oncol; 2008 Nov; 1():21. PubMed ID: 18986533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.